Carmine De Angelis, Associate Professor at Southern Higher School, Naples, shared a post on LinkedIn about a paper he co-authored with colleagues published in European Journal of Cancer:
“Maintaining chemotherapy dose intensity matters in early breast cancer.
Our latest study, just published in the European Journal of Cancer, analyzed patients with HER2-negative early breast cancer treated with neoadjuvant chemotherapy across two Italian centers.
We found that maintaining a high relative dose intensity (RDI >85%) was significantly associated with improved outcomes:
- In TNBC, high RDI correlated with higher pCR rates and better EFS
- In HR+ disease, high RDI was independently linked to longer EFS, even though pCR was unaffected.
These findings highlight the importance of minimizing chemotherapy dose delays or reductions to maximize efficacy in the curative setting.
Congratulations to Roberto Buonaiuto and Federica Martorana, who led this study with great dedication and scientific rigor.”
Title: Association of Neoadjuvant Chemotherapy Dose Intensity with Pathological Complete Response and Event-Free Survival in HER2-Negative Early Breast Cancer
Authors: Roberto Buonaiuto, Federica Martorana, Paola Marino, Federica Mangiacotti, Aldo Caltavituro, Francesco La Spina, Paola Trasacco, Alessandra Longobardi, Vittoria Molinaro, Maria Letizia Cataldo, Martina Pagliuca, Michelino De Laurentiis, Mario Giuliano, Grazia Arpino, Paolo Vigneri, Carmine De Angelis
You can read the full article in European Journal of Cancer.
More posts featuring Carmine De Angelis.